Company intelligence / Profile preview
Cannabis Science, Inc.
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
Overview
Cannabis Science focused on developing cannabinoid-based pharmaceuticals for serious illnesses including skin cancers and HIV/AIDS. The company had several preclinical/early-stage programs but did not achieve FDA approval for any therapy before its SEC license was revoked in October 2019. It engaged in multiple academic collaborations but has not reported recent clinical results or commercial launches.
- Therapeutic areas
- OncologyHematologyPsychiatryNeurologyInfectious Diseases
- Modalities
- Cannabinoid-based therapies (phytocannabinoids)Plant-based medicinesDNA-based immunotherapeutics
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Cannabis Science, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cannabis Science, Inc..